RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE

Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE explained in plain language.

Never miss a new study

Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE trials appear

Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 1

New drug combo aims to boost stem cell transplant success against tough lymphoma

Disease control Ongoing

This study is testing whether adding the drug ibrutinib to a stem cell transplant helps patients with a specific aggressive lymphoma that has returned or not responded to prior treatment. Patients receive either ibrutinib or a placebo (inactive pill) before and for a year after t…

Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE

Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 31, 2026 12:21 UTC

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE

Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE trials appear

New drug combo aims to boost stem cell transplant success against tough lymphoma